ClinicalTrials.gg
CompletedNCT00661479Updated Apr 24, 2013Results posted

An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

A Phase 1/2 interventional study of 400 µg Brimonidine Tartrate Implant and 200 µg Brimonidine Tartrate Implant in Retinitis Pigmentosa, sponsored by Allergan. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-24.

Sponsored by Allergan (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 44 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Enrollment
39th of 78
21 · median 21
Started
2008
the only one that year
Phase 1/2
20 of 119
4 open now
Registered
22nd of 119
by date

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 39th largest by enrollment of the 78 interventional ones that give a count, is the only one that started in 2008, is one of 20 in phase 1/2, and was the 22nd registered.

Retinitis Pigmentosa

278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.

03

Conditions studied

  • Retinitis Pigmentosa

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Retinitis Pigmentosa in both eyes
  • Visual acuity between 20/40 to count fingers

Exclusion criteria

Exclusion Criteria:

  • Growth of new blood vessels in the eye
  • Any intraocular surgery or laser in either eye in the last 6 months prior to Screening visit or between the Screening visit and Day 1
  • Any ocular disease that can interfere with diagnosis and or assessment of disease progression
  • Significant near-sightedness
  • Female patients who are pregnant, nursing, or planning pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    400 µg Brimonidine Tartrate Implant Group B

    400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.

    Drug: 400 µg Brimonidine Tartrate Implant · Other: Sham (no implant)

  • Experimental
    200 µg Brimonidine Tartrate Implant Group B

    200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.

    Drug: 200 µg Brimonidine Tartrate Implant · Other: Sham (no implant)

  • Experimental
    100 µg Brimonidine Tartrate Implant Group B

    100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.

    Drug: 100 µg Brimonidine Tartrate Implant · Other: Sham (no implant)

  • Experimental
    100 µg Brimonidine Tartrate Implant Group A

    100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.

    Drug: 100 µg Brimonidine Tartrate Implant · Other: Sham (no implant)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Change From Baseline in Contrast Sensitivity in the Study Eye

    Change from baseline in contrast sensitivity in the study eye is measured using a Pelli-Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.

    Time frame: Baseline, Month 6

07

Results

Posted Apr 24, 2013

Participant flow

Participant flow — Overall Study
Milestone400 µg Brimonidine Tartrate Implant Group B200 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group A
Started12333
Completed12333
Not completed0000

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · Number of Letters Read Correctly
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Number of Letters Read Correctly400 µg Brimonidine Tartrate Implant Group B200 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group A
Baseline48.5 ± 14.6151.0 ± 14.1852.7 ± 3.794.0 ± 3.46
Change from Baseline at Month 63.2 ± 4.41-1.3 ± 4.043.3 ± 8.500.3 ± 3.79
SecondaryChange From Baseline in Contrast Sensitivity in the Study Eye

Change from baseline in contrast sensitivity in the study eye is measured using a Pelli-Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · Number of Letters Read Correctly
Change From Baseline in Contrast Sensitivity in the Study Eye
Number of Letters Read Correctly400 µg Brimonidine Tartrate Implant Group B200 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group A
Baseline15.5 ± 8.4818.0 ± 7.2122.3 ± 1.533.0 ± 3.46
Change from Baseline at Month 60.8 ± 4.86-0.3 ± 5.864.3 ± 1.15-2.0 ± 1.73

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
400 µg Brimonidine Tartrate Implant Group B—1/12 (8.3%)11/12 (91.7%)
200 µg Brimonidine Tartrate Implant Group B—0/3 (0%)3/3 (100%)
100 µg Brimonidine Tartrate Implant Groups A and B—1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
Event400 µg Brimonidine Tartrate Implant Group B200 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Groups A and B
MyelitisNervous system disorders0/120/31/6
SyncopeNervous system disorders1/120/30/6
Most frequent other events
Showing 10 of 58
Most frequent other events
Event400 µg Brimonidine Tartrate Implant Group B200 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Groups A and B
Conjunctival HyperaemiaEye disorders5/123/35/6
Conjunctival HaemorrhageEye disorders5/122/31/6
Conjunctival OedemaEye disorders2/122/31/6
NasopharyngitisInfections and infestations3/120/32/6
Eye PainEye disorders2/120/32/6
Prostate InfectionInfections and infestations0/70/21/3
ConjunctivitisEye disorders0/121/30/6
Dental CariesGastrointestinal disorders0/121/30/6
PharyngitisInfections and infestations0/121/30/6
Foreign Body Sensation in EyesEye disorders3/120/31/6

Baseline characteristics

Age Continuous
Age Continuous(Years)400 µg Brimonidine Tartrate Implant Group B200 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group ATotal
Mean46.3 ± 18.7056.3 ± 6.0348.7 ± 4.0469.0 ± 5.2951.3 ± 16.36
Sex: Female, Male
Sex: Female, Male(Participants)400 µg Brimonidine Tartrate Implant Group B200 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group B100 µg Brimonidine Tartrate Implant Group ATotal
Female51309
Male720312
08

Study locations

4 sites
  • Arlington, Texas, United States
  • Paris, France
  • Tubingen, Germany
  • Coimbra, Portugal
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Dec 2009 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 3 years 4 months after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2007
First posted
Apr 18, 2008
Start
Jul 2008
Primary completionActual
Dec 2009
CompletionActual
May 2010
Results delay requested
Feb 2, 2011
Results first posted
Apr 24, 2013
Last update
Apr 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00661479
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 18, 2008
Start date
Jul 2008
Primary completion
Dec 2009
Completion
May 2010
Results posted
Apr 24, 2013
Last update
Apr 24, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion